Skip to main content

Advertisement

SpringerLink
Log in

Concurrent chemoradiotherapy with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Introduction

Concurrent chemoradiotherapy (CCRT) has been widely used during the past decades in clinical trials and has now become a common treatment option in many clinical settings. The present study was designed to evaluate the efficacy of combining radiation with low-dose docetaxel in DU-145 prostate cancer xenograft models.

Methods

Male BALB/c nude mice bearing human DU-145 prostate tumors were assigned to four treatment groups: (1) control, (2) docetaxel (10 mg/kg/week, i.v., ×3 weeks), (3) radiation (2 Gy, q.d. ×5, ×3 weeks), (4) CCRT (the combination of docetaxel and radiation). Treatment efficacy was determined by tumor volume and tumor regression measurements. The extent of apoptosis in tumors in response to treatments was assessed via terminal deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) assay. In addition, immunohistochemical staining of CD34 was done to quantify microvessel density in the tumors.

Results

Our in vivo studies using DU-145 xenograft models in nude mice showed that CCRT compared to either alone significantly inhibited tumor growth, and the percentages of tumor regression were 32.6, 44.2, and 68.6 % for docetaxel, radiation, and CCRT, respectively. Moreover, CCRT did not significantly affected mice weight as compared to docetaxel or radiation alone. TUNEL assays showed that significantly more apoptotic cells were induced in the tumors treated with CCRT than either treatment alone. Anti-CD34 immunohistochemical staining indicated that CCRT significantly inhibited tumor angiogenesis.

Conclusion

These findings suggest that CCRT with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts, by enhancing apoptosis and suppressing angiogenesis. Based on these preclinical findings, we suggest that CCRT for the treatment of prostate cancer deserves further development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.

    Article  PubMed  Google Scholar 

  2. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D’Amico AV, et al. Prostate cancer, version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2012;10:1081–7.

    CAS  Google Scholar 

  3. Fung-Kee-Fung SD, Porten SP, Meng MV, Kuettel M. The role of active surveillance in the management of prostate cancer. J Natl Compr Cancer Netw. 2013;11:183–7.

    Google Scholar 

  4. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005;55:300–18.

    Article  PubMed  Google Scholar 

  5. Hainsworth JD, Burris HA 3rd, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol. 2001;19:3500–5.

    CAS  PubMed  Google Scholar 

  6. Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:130–5.

    Article  CAS  PubMed  Google Scholar 

  7. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol. 2006;24:3657–63.

    Article  CAS  PubMed  Google Scholar 

  8. Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res. 1996;56:1842–50.

    CAS  PubMed  Google Scholar 

  9. Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res. 1997;3:2431–8.

    CAS  PubMed  Google Scholar 

  10. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

    Article  CAS  PubMed  Google Scholar 

  11. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.

    Article  CAS  PubMed  Google Scholar 

  12. Kumar P, Perrotti M, Weiss R, Todd M, Goodin S, Cummings K, et al. Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol. 2004;22:1909–15.

    Article  CAS  PubMed  Google Scholar 

  13. Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, Piantelli M, et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett. 2008;270:229–33.

    Article  CAS  PubMed  Google Scholar 

  14. Xu L, Yang D, Wang S, Tang W, Liu M, Davis M, et al. (−)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther. 2005;4:197–205.

    Article  CAS  PubMed  Google Scholar 

  15. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm–general principles. Nat Clin Pract Oncol. 2007;4:86–100.

    Article  CAS  PubMed  Google Scholar 

  16. Sanfilippo N, Hardee ME, Wallach J. Review of chemoradiotherapy for high-risk prostate cancer. Rev Recent Clin Trials. 2011;6:64–8.

    Article  CAS  PubMed  Google Scholar 

  17. Milas L. Docetaxel/radiation combinations: rationale and preclinical findings. Clin Lung Cancer. 2002;3(Suppl 2):S29–36.

    Article  PubMed  Google Scholar 

  18. Perrotti M, Doyle T, Kumar P, McLeod D, Badger W, Prater S, et al. Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10). Urol Oncol. 2008;26:276–80.

    Article  CAS  PubMed  Google Scholar 

  19. Chen RC, Rosenman JG, Hoffman LG, Chiu WK, Wang AZ, Pruthi RS, et al. Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. BJU Int. 2012;110:E721–6.

    Article  CAS  PubMed  Google Scholar 

  20. Hainsworth JD, Burris HA 3rd, Greco FA. Weekly administration of docetaxel (taxotere): summary of clinical data. Semin Oncol. 1999;26:19–24.

    CAS  PubMed  Google Scholar 

  21. Hainsworth JD. Practical aspects of weekly docetaxel administration schedules. Oncologist. 2004;9:538–45.

    Article  CAS  PubMed  Google Scholar 

  22. Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78:11–8.

    Article  PubMed  Google Scholar 

  23. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61:3369–72.

    CAS  PubMed  Google Scholar 

  24. Ahmad M, Khurana NR, Jaberi JE. Ionizing radiation decreases capillary-like structure formation by endothelial cells in vitro. Microvasc Res. 2007;73:14–9.

    Article  CAS  PubMed  Google Scholar 

  25. Tsai JH, Makonnen S, Feldman M, Sehgal CM, Maity A, Lee WM. Ionizing radiation inhibits tumor neovascularization by inducing ineffective angiogenesis. Cancer Biol Ther. 2005;4:1395–400.

    Article  CAS  PubMed  Google Scholar 

  26. Lorke DE, Wenzel S, Siebert K, Zywietz F. Microvascular and tumor cell alterations during continuous hyperfractionated irradiation: an electron microscopic investigation on the rat R1H rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 1999;44:895–904.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China

    L. Wang, X. Zheng, X. Wang, S. Li, L. Zhang & Z. Yang

  2. Department of Oncology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang, 441021, China

    L. Wang

  3. Department of Urology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang, 441021, China

    X. Huang

Authors
  1. L. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. X. Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X. Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. X. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Z. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to X. Zheng.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, L., Huang, X., Zheng, X. et al. Concurrent chemoradiotherapy with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Clin Transl Oncol 16, 567–572 (2014). https://doi.org/10.1007/s12094-013-1120-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-013-1120-3

Keywords

Search

Navigation